Protalix BioTherapeutics (PLX) Cost of Revenue (2010 - 2026)

Protalix BioTherapeutics' Cost of Revenue history runs 17 years deep, the most recent figure standing at $4.1 million for Q1 2026.

• In Q1 2026, Cost of Revenue fell 49.55% year-over-year to $4.1 million; the TTM figure through Mar 2026 stood at $22.9 million (down 23.27% YoY), while the FY2025 annual figure was $27.0 million, up 11.0% from the prior year.
• Cost of Revenue was $4.1 million for Q1 2026 at Protalix BioTherapeutics, down from $4.6 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $9.5 million in Q2 2024 to a low of $2.4 million in Q4 2022.
• Historically, Cost of Revenue has averaged $5.8 million across 5 years, with a median of $5.9 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Cost of Revenue jumped 269.46% in 2023, then plunged 56.12% in 2024.
• A 5-year view of Cost of Revenue shows it stood at $2.4 million in 2022, then surged by 269.46% to $8.9 million in 2023, then slumped by 56.12% to $3.9 million in 2024, then climbed by 18.86% to $4.6 million in 2025, then declined by 10.65% to $4.1 million in 2026.
• The last three Cost of Revenue figures came in at $4.1 million (Q1 2026), $4.6 million (Q4 2025), and $8.3 million (Q3 2025), per Business Quant data.